(Q51021960)

English

Pegylated liposomal doxorubicin (Caelyx®) and oral vinorelbine in first-line metastatic breast cancer patients previously treated with anthracyclines.

scientific article published in June 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Pegylated liposomal doxorubicin (Caelyx®) and oral vinorelbine in first-line metastatic breast cancer patients previously treated with anthracyclines. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Simonetta Bianchi

15

object named as

Bianchi S

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

author name string

Livi L

1

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Scotti V

3

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

De Luca Cardillo C

4

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Galardi A

5

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Iermano C

6

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Sanchez L

7

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Nori J

8

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Mangoni M

9

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Franzese C

10

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Orzalesi L

11

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Bertocci S

12

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Agresti B

13

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Masoni T

14

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Cataliotti L

16

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Biti G

17

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

publication date

1 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Journal of Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

23

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

3

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

158-162

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study.

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

Pegylated liposomal doxorubicin in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

The effects of food on the pharmacokinetic profile of oral vinorelbine

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

Non-small-cell lung cancer in elderly patients: influence of age on vinorelbine oral pharmacokinetics

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.3.158

21 January 2018

Identifiers

10.1179/JOC.2011.23.3.158

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21742585

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51021960&oldid=1672301988"